Netherlands
Medical device market intelligence for Netherlands. Regulatory changes, competitor moves, and procurement trends.
Country table last refreshed: Aug 7, 2026 (may lag). 7-day count above is live-recomputed (table had 45).
Last 7 days
Draft guideline on the requirements for demonstrating therapeutic equivalence for nasal products
Clinical trial applications advice pilot becomes permanent
Quality, preclinical and clinical aspects of gene therapy medicinal products - Scientific guideline - European Medicines Agency (EMA)
Physical frailty: instruments for baseline characterisation of older populations in clinical trials - Scientific guideline - European Medicines Agency (EMA)
Medical devices legislation - European Medicines Agency (EMA)
Concept paper on the guideline revision on good pharmacogenomic practice
Clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD) - Scientific guideline - European Medicines Agency (EMA)
ICH M11 guideline, clinical study protocol template and technical specifications - Scientific guideline - ema.europa.eu
EMA Public Declaration of Interests form - European Medicines Agency (EMA)
Clinical investigation of medicinal products in the treatment of lipid disorders - Scientific guideline - European Medicines Agency (EMA)
Expert decision and opinion in the context of the Clinical Evaluation Consultation Procedure (CECP) - European Medicines Agency (EMA)
Clinical evaluation of new vaccines - Scientific guideline - European Medicines Agency (EMA)
Non-clinical requirements for radiopharmaceuticals - Scientific guideline - European Medicines Agency (EMA)
Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials - Scientific guideline - European Medicines Agency (EMA)
Clinical development of fixed combination medicinal products - Scientific guideline - European Medicines Agency (EMA)
ICH E6 Good clinical practice - Scientific guideline - European Medicines Agency (EMA)
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 September - 1 October